In a prospective, multicenter study of 203 men with BPH receiving dutasteride in Japan, a > 10% increase in PSA levels after 1 year of treatment significantly predicted the risk of a prostate cancer diagnosis [24]. The gene discussed is KLK3; the disease is benign prostatic hyperplasia.